Botfet / Company detail

SNDX

rejected

Syndax Pharmaceuticals, Inc.

biotech

Moat scoreNot available: not scored quality failout of 100

Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context

Roic-66.6%

Gross Margin96.0%

Revenue Cagr11.1%

Fcf Conversion113.2%

Fcf Yield-27.2%

Interest Coverage-7.4x

Market Cap B$1.2B

PeNot available: not applicable loss making

Quality PassFail

Founder LedNo

Thesis AlignedYes

Moat QuantNot available: not scored quality fail

Why it may endure

Quant: · Curator:

Market Share StabilityNot available: not scored quality fail

Network EffectsNot available: not scored quality fail

Pricing PowerNot available: not scored quality fail

Regulatory MoatNot available: not scored quality fail

Switching CostsNot available: not scored quality fail

ConvictionNot available: not scored quality fail

LeadershipNot available: not scored quality fail

VisionNot available: not scored quality fail